Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder
5 FDA Decisions to Watch in the First Quarter of 2026
Telehealth Provider Hims Goes After Novo's Weight Loss Pill with Compounded Version
Biotech in 2025: A Retrospective
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
#JPM26: Novo Nordisk CEO Says Pharma Can Learn From the GLP-1 Compounding Boom
Pfizer Searches for Novel Tumor-Selective Antigens With $865M+ Cartography Pact
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer
3 Trends Shaping the GLP-1 Landscape
Madrigal Eyes Combination MASH Therapy with Pfizer Deal
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
STAT+: Novo Nordisk Strikes Deal with U.S. Startup to Develop Oral Obesity, Diabetes Drugs
New CagriSema Data Show Improvement over Semaglutide
JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview
Office CMBS Delinquency Rate Spikes to Record 12.3%, Much Worse than Financial Crisis Meltdown Peak
Labiotech’s 15 Biopharma Companies to Watch in 2026
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Novo Combination Obesity Shot Meets Goal in Diabetes Trial
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Aspect Biosystems and Novo Nordisk – Enter New Phase of Partnership to Develop Curative Medicines for Diabetes
GLP-1 Drugs Linked to Pancreatitis, Gallbladder Problems
Politicization Runs Deeper than Ever at FDA, Risking Long-Term Impacts
Health Equity & Access Weekly Roundup: February 20, 2026
Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention
Viking Gets Commercial Chief While Other Obesity Biotechs Sell; Novo's Uli Stilz Steps Down
FDA to Meet Novo Nordisk on Troubled Site; AbbVie Buys Drug-Device Factory
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
CMS's Medicare Price Negotiations Start Round Three
Anthropic: It’s “Critical” To Bring Company Products to EHR
Nine Biotech Companies that Could Revolutionize Obesity Treatments
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
AZ Signals All-In on Obesity via CSPC Deal for $1.2B up Front
Ventus Therapeutics – Announces First Patient Dosed in Phase 2 Clinical Trial of VENT-03, a Novel Small Molecule cGAS Inhibitor, in Patients with Lupus
Novartis Doesn’t Have a GLP-1. They Don’t Miss It In a World Of Me-Toos
Embattled Novo Nordisk Considers Buying a Monthly GLP-1 to Bolster Portfolio
FDA Asks Lilly, Novo to Remove Suicide Warnings From GLP-1 Labels
5 Questions Facing Biopharma in 2026
Should Drug Companies Be Advertising to Consumers?
Hims & Hers Plans to Acquire Eucalyptus for $1.15B
11 Companies Hiring Manufacturing Professionals Now
Valo Health CEO: We Don’t Want Investors To Drive the Science
The New Wave of Protein Is for the Girls
The New Gold Rush in Brain Science
Novo Nordisk, BioMarin Make AI Moves; Bristol Myers Welcomes Neurology Exec From Eisai
Novo Slides 14% as Early Q4 Results Predict Sales Decline for 2026
FDA Policy Tracker 2026: Priority Vouchers Questioned, PRVs Return
Hims & Hers Stock Crashes After FDA Announces Plans to Take 'Decisive Steps' Against GLP-1 Compounds
Novo Nordisk Sues Hims over Wegovy Patent Infringement, Considers Seeking 'Hundreds of Millions' In Damages